Advanced Enzyme Technologies Share price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 1,88,103 shares, with a market capitalization of ₹111976150. Its Average Traded Price (ATP) is ₹294.37, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 10 @ ₹292.90.
Advanced Enzyme Technologies has an upper circuit limit of ₹354.40 and a lower circuit limit of ₹236.30. The total value traded stands at ₹5.54 CR, and the delivery percentage for the day is 64.25%.
The stock is currently traded with a market lot size of 1. Advanced Enzyme Technologies also offers a dividend yield of 1.81%.
Advanced Enzyme Technologies share price chart
Advanced Enzyme Technologies Share Key Metrics
Volume
1.88 L
Market Cap
3279.78 CR
LTQ@LTP
10@292.90
ATP
294.37
Var Margin
19.28 %
Circuit Range
236.3-354.4
Delivery %
64.25 %
Value
5.54 CR
ASM/GSM
No
Market Lot
1
Advanced Enzyme Technologies Resistance and Support
Pivot 295.02
Resistance
First Resistance
298.54
Second Resistance
301.72
Third Resistance
305.24
Support
First Support
291.84
Second Support
288.32
Third Support
285.14
Advanced Enzyme Technologies Shareholding Pattern
View More- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Advanced Enzyme Technologies Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-08 | Quarterly Results & Buy Back |
| 2026-05-09 | Audited Results & Dividend |
| 2026-01-31 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-08-02 | Quarterly Results |
| 2025-05-13 | Audited Results |
| 2025-02-08 | Quarterly Results |
| 2024-11-09 | Quarterly Results |
| 2024-08-10 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-24 | 2026-07-24 | View More |
Advanced Enzyme Technologies News
Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Advanced Enzyme Technologies has made the audio recording of its conference call for the unaudited financial results for the quarter ended June 30, 2026, available on the company website. Investors can access the discussion on the company's Q1 FY27 performance.
Aug 12 2026 21:09:22
Advanced Enzyme Technologies Ltd - 540025 - Corporate Action-Updates on Buy back
Advanced Enzyme Technologies Board approved an open market buyback program of up to ₹69.7 crore. The maximum buyback price is set at ₹500 per share, offering a significant premium over the current market price, and signals management's confidence.
Aug 11 2026 18:27:09
Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares
Advanced Enzyme Tech's board approved a share buyback plan of up to Rs. 69.7 crore (1.394 million shares) at a maximum price of Rs. 500 per share. The buyback will occur through open market purchases, with promoters excluded from participating.
Aug 11 2026 18:19:08
Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Advanced Enzyme Technologies reported Q1 FY27 revenue of Rs.189.8 crore, a 2% increase year-on-year. However, net profit declined 5% YoY to Rs.38.6 crore, and EBITDA fell 10% YoY to Rs.51 crore, reflecting margin pressure.
Aug 08 2026 17:29:58
Advanced Enzyme Technologies Ltd - 540025 - Corporate Action-Buy back
Advanced Enzyme Tech board approved an equity share buyback program for up to Rs.69.7 crore. The buyback will be conducted at a maximum price of Rs.500 per share via the open market mechanism, intending to repurchase up to 1.39 million shares.
Aug 08 2026 13:56:02
Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Acquisition
Advanced Enzyme Tech acquired the remaining 4.28% equity shares of JC Biotech Private Limited for ₹7.979 crore. This acquisition makes JC Biotech a wholly-owned subsidiary, aiming to optimize business synergies within the biopharmaceuticals segment.
Aug 08 2026 13:46:48
Advanced Enzyme Technologies Ltd - 540025 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 08, 2026
Advanced Enzyme Tech reported Q1 FY27 cons. revenue of ₹189.79 cr (up 2.08% YoY) and net profit of ₹38.59 cr (down 4.58% YoY). The board also approved a buyback of up to ₹69.7 cr at a maximum price of ₹500 per share, and completed the acquisition of remaining stakes in JC Biotech Private Limited and Advanced Nutrazyme Private Limited, making both wholly owned subsidiaries.
Aug 08 2026 13:24:53
Advanced Enzyme Technologies Management
| Name | Position |
|---|---|
| Sanjay Basantani | Company Secretary & Compliance Officer, Head-Legal |
| Vasant Rathi | Chairman |
Advanced Enzyme Technologies Similar Stocks
Aarti Drugs Ltd.
417.80
-9.30 (2.18%)
Indraprastha Medical Corporation Ltd.
352.35
-5.45 (1.52%)
SMS Pharmaceuticals Ltd.
373.05
4.80 (1.30%)
Kwality Pharmaceuticals Ltd.
3390.10
-0.40 (0.01%)
Ind-Swift Laboratories Ltd.
366.85
-1.30 (0.35%)
Solara Active Pharma Sciences Ltd.
640.35
-3.10 (0.48%)
Dishman Carbogen Amcis Ltd.
176.85
-4.98 (2.74%)
Beta Drugs Ltd.
2137.00
-69.80 (3.16%)
Advanced Enzyme Technologies FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in ADVENZYMES
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
+ Free 1st Year AMC
Or Download Choice FinX App
Invest in ADVENZYMES
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade